Crescent Sterling, Ltd. Amgen Inc Transaction History

Crescent Sterling, Ltd.

$89.4 Billion
Q2 2025

A detailed history of Crescent Sterling, Ltd. transactions in Amgen Inc stock. As of the latest transaction made, Crescent Sterling, Ltd. holds 8,951 shares of AMGN stock, worth $2.6 Million. This represents 2.8% of its overall portfolio holdings.

Number of Shares

8,951

Previous 9,489 5.67%

Holding current value

$2.6 Million

Previous $2.96 Billion 15.46%

% of portfolio

2.8%

Previous 3.03%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 04, 2025	SELL	$262.28 - $309.85 $141,106 - $166,699	-538 Reduced 5.67%	8,951 $2.5 Billion
Q1 2025 Apr 14, 2025	BUY	$258.59 - $327.36 $46,546 - $58,924	180 Added 1.93%	9,489 $2.96 Billion
Q4 2024 Jan 13, 2025	BUY	$258.78 - $328.31 $113,345 - $143,799	438 Added 4.94%	9,309 $2.43 Billion
Q3 2024 Oct 15, 2024	SELL	$309.38 - $337.38 $25,678 - $28,002	-83 Reduced 0.93%	8,871 $2.86 Billion
Q2 2024 Jul 17, 2024	SELL	$262.75 - $319.31 $95,641 - $116,228	-364 Reduced 3.91%	8,954 $2.8 Billion
Q1 2024 Apr 22, 2024	BUY	$268.87 - $324.56 $32,533 - $39,271	121 Added 1.32%	9,318 $2.65 Billion
Q4 2023 Jan 10, 2024	SELL	$255.7 - $288.46 $64,947 - $73,268	-254 Reduced 2.69%	9,197 $2.65 Billion
Q3 2023 Oct 23, 2023	BUY	$218.65 - $271.46 $40,887 - $50,763	187 Added 2.02%	9,451 $2.54 Billion
Q2 2023 Aug 03, 2023	BUY	$214.27 - $253.37 $51,853 - $61,315	242 Added 2.68%	9,264 $2.06 Billion
Q1 2023 Apr 21, 2023	BUY	$225.79 - $275.2 $63,672 - $77,606	282 Added 3.23%	9,022 $2.18 Billion
Q4 2022 Jan 19, 2023	BUY	$229.03 - $291.01 $2 Million - $2.54 Million	8,740 New	8,740 $2.3 Billion

Others Institutions Holding AMGN

# of Institutions

3,278

Shares Held

442M

Call Options Held

6.15M

Put Options Held

7.25M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $155B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crescent Sterling, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Crescent Sterling, Ltd. with notifications on news.

Account

Crescent Sterling, Ltd. Amgen Inc Transaction History